Table 3.
Comparison of biopsy-proven CMV colitis patients with and without LDLT.
| Category | Subgroups of Non-LDLT | All Non-LDLT (n = 53) |
LDLT (n = 2) |
p Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sepsis (n = 13) | UC (n = 12) |
ESRD (n = 11) |
DM (n = 9) |
Chemotherapy * (n = 8) |
AIDS (n = 3) |
SLE (n = 1) |
||||
| Age, mean ± SD (range) (years) | 80.5 ± 10.7 | 63.9 ± 17.5 | 68.2 ± 7.5 | 70.6 ± 6.9 | 61.3 ± 18.4 | 40.3 ± 14.1 | 69 | 68.2 ± 15.9 | 63.0 ± 32.0 | 0.38 |
| Gender | ||||||||||
| Male, n (%)/Female, n (%) | 6 (46.2)/7 (53.8) | 5 (41.7)/7 (58.3) | 5 (45.5)/6 (54.5) | 3 (33.3)/6 (66.7) | 7 (87.5)/1 (12.5) | 3 (100.0)/0 (0) | 0 (0)/1 (100) | 27 (51.0)/26 (49.0) | 1 (50.0)/1 (50.0) | 1.00 |
| Cancer history, n (%) | 1 (7.7) | 0 (0) | 0 (0) | 0 (0) | 8 (100) | 0 (0) | 0 (0) | 9 (17.0) | 1 (50.0) | 0.33 |
| Clinical symptoms | ||||||||||
| Bloody stool, n (%) | 6 (46.2) | 8 (66.7) | 9 (81.8) | 7 (77.8) | 4 (50) | 0 (0) | 1 (100) | 35 (66.0) | 0 (0) | 0.13 |
| Diarrhea, n (%) | 5 (38.5) | 1 (8.3) | 2 (18.2) | 1 (11.1) | 1 (12.5) | 2 (66.7) | 0 (0) | 12 (22.6) | 1 (50) | 1.00 |
| Abdominal pain, n (%) | 1 (7.7) | 2 (16.7) | 0 (0) | 2 (22.2) | 2 (25) | 1 (33.3) | 0 (0) | 8 (15.1) | 2 (100) | 1.00 |
| Fever, n (%) | 2 (15.4) | 2 (16.7) | 1 (9.1) | 1 (11.1) | 2 (25) | 0 (0) | 0 (0) | 8 (15.1) | 0 (0) | 1.00 |
| Lesion site | ||||||||||
| Cecum, n (%) | 3 (23.1) | 0 (0) | 1 (9.1) | 0 (0) | 4 (50) | 0 (0) | 0 (0) | 8 (15.1) | 0 (0) | 1.00 |
| Ascending colon, n (%) | 2 (15.4) | 1 (8.3) | 0 (0) | 0 (0) | 3 (37.5) | 1 (33.3) | 0 (0) | 7 (13.2) | 1 (50) | 1.00 |
| Transverse colon, n (%) | 1 (7.7) | 0 (0) | 1 (9.1) | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 3 (5.7) | 2 (100) | 0.11 |
| Descending colon, n (%) | 2 (15.4) | 2 (16.7) | 2 (18.2) | 1 (11.1) | 2 (25) | 0 (0) | 1 (100) | 10 (18.9) | 1 (50) | 1.00 |
| Sigmoid colon, n (%) | 2 (15.4) | 5 (41.7) | 1 (9.1) | 2 (22.2) | 1 (12.5) | 0 (0) | 0 (0) | 11 (20.8) | 1 (50) | 1.00 |
| Rectum, n (%) | 4 (30.8) | 4 (33.3) | 6 (54.5) | 5 (55.6) | 3 (37.5) | 2 (66.7) | 0 (0) | 24 (45.3) | 0 (0) | 1.00 |
| Serum laboratory test | ||||||||||
| N/L ratio, mean ± SD | 14.9 ± 23.9 | 11.1 ± 25.9 | 6.8 ± 4.8 | 15.5 ± 30.7 | 6.9 ± 4.9 | 3.1 ± 2.4 | 3.6 | 11.1 ± 21.0 | 1.96 ± 1.5 | 0.13 |
| Anti-CMV IgM | ||||||||||
| Positive, n (%) | 0 (0) | 2 (16.7) | 1 (9.1) | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 3 (5.7) | 0 (0) | 1.00 |
| Negative, n (%) | 5 (38.5) | 7 (58.3) | 1 (9.1) | 2 (22.2) | 3 (37.5) | 1 (33.3) | 1 (100) | 20 (37.7) | 2 (100) | 0.16 |
| Not available, n (%) | 8 (61.5) | 3 (25) | 9 (81.8) | 6 (66.7) | 5 (62.5) | 2 (66.7) | 0 (0) | 30 (56.6) | 0 (0) | 0.20 |
| Anti-CMV IgG | ||||||||||
| Positive, n (%) | 5 (38.5) | 6 (50) | 1 (9.1) | 2 (22.2) | 3 (37.5) | 1 (33.3) | 1 (100) | 19 (35.8) | 2 (100) | 0.14 |
| Negative, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Not available | 8 (61.5) | 6 (50) | 10 (90.9) | 7 (77.8) | 5 (62.5) | 2 (66.7) | 0 (0) | 34 (64.2) | 0 (0) | 0.14 |
| CMV PCR DNA amplification assays | ||||||||||
| Positive, n (%) | 4 (30.8) | 5 (41.7) | 1 (9.1) | 0 (0) | 4 (50) | 0 (0) | 0 (0) | 14 (26.4) | 1 (50) | 0.47 |
| Negative, n (%) | 2 (15.4) | 5 (41.7) | 0 (0) | 2 (22.2) | 3 (37.5) | 3 (100) | 1 (100) | 14 (26.4) | 1 (50) | 0.47 |
| Not available, n (%) | 7 (53.8) | 2 (16.7) | 10 (90.9) | 7 (77.8) | 1 (12.5) | 0 (0) | 0 (0) | 25 (47.2) | 0 (0) | 0.49 |
| Pathology | ||||||||||
| Inclusion bodies, n (%) | 8 (61.5) | 5 (41.7) | 5 (45.5) | 6 (66.7) | 4 (50) | 1 (33.3) | 1 (100) | 30 (56.6) | 2 (100) | 0.50 |
| CMV IHC staining, n (%) | 13 (100) | 12 (100) | 11 (100) | 9 (100) | 8 (100) | 3 (100) | 1 (100) | 53 (100) | 2 (100) | 1.00 |
| Anti-viral therapy | ||||||||||
| Ganciclovir, n (%) | 4 (30.8) | 4 (33.3) | 3 (27.3) | 2 (22.2) | 1 (12.5) | 2 (66.7) | 1 (100) | 17 (32.1) | 0 (0) | 1.00 |
| Valganciclovir, n (%) | 4 (30.8) | 5 (41.7) | 2 (18.2) | 1 (11.1) | 4 (50) | 0 (0) | 0 (0) | 12 (22.6) | 0 (0) | 1.00 |
| Ganciclovir plus Valganciclovir, n (%) | 2 (15.4) | 2 (16.7) | 2 (18.2) | 1 (11.1) | 1 (12.5) | 0 (0) | 0 (0) | 8 (15.1) | 2 (100) | 0.04 |
| No treatment, n (%) | 3 (23.1) | 1 (8.3) | 4 (36.4) | 5 (55.6) | 2 (25) | 1 (33.3) | 0 (0) | 16 (30.2) | 0 (0) | 1.00 |
| Complications | ||||||||||
| Perforation, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (25) | 0 (0) | 0 (0) | 2 (3.8) | 0 (0) | 1.00 |
*: chemotherapy for colon cancer (n = 2, 3.6%), cancer of non-gastrointestinal tract (n = 6, 10.9%).